NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT04534205 2026-04-15
AHEAD-MERIT
BioNTech SE
Phase 2/3 Recruiting
NCT06984328 2026-04-08
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Active not recruiting
NCT01822652 2026-04-06
GRAIN
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05047094 2026-04-06
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT05533697 2026-04-03
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT07501650 2026-03-30
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
Thomas Jefferson University
Phase 1 Recruiting
NCT05669846 2026-03-23
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
University of Pittsburgh
Phase 2 Recruiting
NCT05537740 2026-03-20
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting